Entera Bio Ltd. Free Cash Flow Margin

Free Cash Flow Margin of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow Margin growth rates and interactive chart. Free cash flow margin or Free cash flow-to-sales is a performance ratio that measures operating cash flows after deduction of capital expenditures (free cash flow) relative to sales. Free cash flows (FCF) is an important metric in assessing a company's financial condition and determining its intrinsic valuation. FCF/sales is tracked over time and can be compared to a company's historical record or to peers. Free cash flow is useful because it takes out non-cash items out of earnings and only looks at the underlying operating cash coming in and out of a business minus the necessary capital expenditures.


Highlights and Quick Summary

  • Annual Free Cash Flow Margin for 2019 was -3796.19% (a 92.43% increase from previous year)
  • Annual Free Cash Flow Margin for 2018 was -1972.8% (a -Infinity% decrease from previous year)
  • Twelve month Free Cash Flow Margin ending June 29, 2020 was -4326.56% (a 24.28% increase compared to previous quarter)
  • Twelve month trailing Free Cash Flow Margin decreased by -Infinity% year-over-year
Trailing Free Cash Flow Margin for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-4326.56% -3481.29% -1217.26% 0.0%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow Margin of Entera Bio Ltd.

Most recent Free Cash Flow Marginof ENTX including historical data for past 10 years.

Interactive Chart of Free Cash Flow Margin of Entera Bio Ltd.

Entera Bio Ltd. Free Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -3796.19%
2018 -1972.8%
2017 0.0%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.